Version June 2024
| Class | Drug | Dose |
| Pentavalent antimonials*¶Δ | Sodium stibogluconate | 20 mg SbV/kg◊ intravenously or intramuscularly per day for 28 days |
| Meglumine antimoniate | 20 mg SbV/kg◊ intravenously or intramuscularly per day for 30 days | |
| Amphotericin | Amphotericin B deoxycholate | 0.5 to 1 mg/kg intravenously per day or every other day, up to total cumulative dose of 20 to 45 mg/kg |
| Liposomal amphotericin B (AmBisome) | 3 mg/kg intravenously once daily up to total cumulative dose of 20 to 60 mg/kg | |
| Miltefosine | Miltefosine§ | 2.5 mg/kg orally (maximum 150 mg) in three divided doses for 28 days; if weight is 30 to 44 kg, give 50 mg orally in divided doses twice daily for 28 days |
| Pentamidine | Pentamidine isethionate | 2 to 4 mg/kg pentamidine base intravenously or intramuscularly every other day or three times per week, for 15 or more doses until healed (this is considered a lesser alternative) |
SbV: pentavalent antimony.
* Pentavalent antimonials may be administered with pentoxifylline (400 mg orally three times a day) for synergistic activity.
¶ Effective dose for weight >75 kg may require higher dose off-label (with attendant gastrointestinal effects), aiming for >2.5 mg/kg dose.
Δ Not commercially available in the United States. It may be possible to obtain meglumine antimoniate via investigational new drug application to the US Food and Drug Administration (FDA).
◊ Doses are expressed as mg of pentavalent antimony content. Meglumine antimoniate contains 81 mg SbV/mL versus sodium stibogluconate, which has 100 mg SbV/mL.
§ Miltefosine is FDA approved and commercially available in the United States. Miltefosine should not be used in females of childbearing age unless a validated contraceptive method is used during treatment and for at least 6 months following treatment.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
